Statement Society for Immunotherapy of Cancer #COVID19👇Insights from immuno-oncology: Access to #IL6 therapies (#tocilizumab, #sarilumab, #siltuximab) Pending peer review #JITC -#compassionateuse #clinicaltrials & IRB U.S. FDA Genentech Regeneron Sanofi Paolo A. Ascierto Bernard A Fox sitcancer.org/research/covid…

Congrats #TIIL member Max JL on ASCO #ASCO21 Trial in Progress Poster! Phase I/II trial encorafenib+/-binimetinib+nivo+low-dose ipi in BRAF #melanoma. Attempting to tread the needle on efficacy vs tox in the highest risk pts. Huge translational potential in this study!

Oncology phase I trials have been referred to as ‘toxicity trials’. The last decade has demonstrated that phase I trials have ORRs of ~20%, (this is within the range of ORRs of several FDA -approved drugs, making them potentially valid therapeutic options nature.com/articles/s4157…

Dr. Paul De Santis, PharmD ASCO Publications Dan Olson Merck National Comprehensive Cancer Network (NCCN) UPMC Hillman Cancer Center Moffitt Cancer Center UChicagoCancerCenter Melanoma Research Melanoma Research Foundation Melanoma Network MAC - Melanoma Action Coalition Deborah Thomassen Save Your Skin Foundation PittDeptofMed These data suggest PD1+CTLA4 should be SOC in 1st or 2nd line & also seems to suggest PD1 + low dose ipi as a strong backbone for novel combos - LAG3? BRAF-MEK in high risk disease? Max JL clinicaltrials.gov/ct2/show/NCT04…

ML models in genomics are now routinely capable of generating 100-1000s of robust hypotheses - many/most of which are novel. It takes like months to validate one or a few of these & requires diverse expertise to make this happen 1/

Important work from #TIIL PI Dr. Riyue Sunny Bao, PhD on immuno-genomic determinants of survival in neuroblastoma! Great work! jitc.bmj.com/content/9/7/e0…

Ipilimumab Combination Dosing: Less is More - Clinical Cancer Research Commentary from Max JL & I to emphasize low-dose ipi as active & less toxic across multiple #melanoma trials now. I'm convinced & don't use the 3 mg/kg ipi dose anymore. UPMC Hillman Cancer Center UPMC Hematology & Oncology Fellowship Program clincancerres.aacrjournals.org/content/early/…

Personalized Cancer Tmt: Cancer meets its nemesis in reprogrammed blood cells: bit.ly/1hifqtv Eric Topol